FINWIRES · TerminalLIVE
FINWIRES

加拿大國家銀行稱,製造業是加拿大各省經濟成長的薄弱環節。

By

-- 加拿大國家銀行表示,雖然穩定的資料流使得追蹤加拿大整體經濟變得更加容易,但分析省級層級的成長卻並非易事。 該銀行指出,上週,加拿大統計局發布了首份按行業劃分的省份國內生產毛額(GDP)估算數據,概述了2025年的經濟狀況。 加拿大國家銀行表示,毫無疑問,與美國的貿易衝突是影響2025年經濟格局最主要的事件,加劇了各地區之間的經濟差距。成長率最低的三個省份——魁北克省(0.6%)、安大略省(1.3%)和曼尼托巴省(1.3%)(而全國平均為1.6%)——都擁有比全國平均更高的製造業。 該銀行指出,由於關稅高於加拿大平均水平,製造業對這些省份的經濟成長產生了負面影響。 魁北克省受製造業疲軟的影響最為嚴重,因為它面臨全國最高的關稅。 安大略省的製造業受到的負面影響相對較小,儘管其關稅也幾乎同樣高——位居加拿大第二。然而,報告指出,這並未阻止安大略省經濟表現不佳,尤其是由於人口成長率低於往年(0.3%,而全國平均為0.6%)。 加拿大國家銀行表示,儘管2025年的經濟將受到貿易衝突和人口結構變化的影響,但這兩個因素也將持續影響今年的經濟表現。

Related Articles

Australia

Citigroup Adjusts Price Target on Marathon Petroleum to $257 From $243, Maintains Neutral Rating

Marathon Petroleum (MPC) has an average rating of overweight and mean price target of $253.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $256.58, Change: $+4.04, Percent Change: +1.60%

$MPC
Research

Research Alert: Peg Reports Strong Q1 Beat; On Track For $4.2b Capex And 7% Eps Growth In 2026

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PEG reported Q1 2026 adjusted EPS of $1.55 vs. $1.43 (+8.4% Y/Y, +8.5% vs. consensus), supported by higher PSE&G margins from regulated infrastructure investments and customer growth, partially offset by higher depreciation and interest expense. PSEG Power earnings increased due to higher realized power prices and lower O&M costs, offset by lower generation volumes. We see the company as on target for $4.2B full-year 2026 capex guidance after deploying ~$0.8B in Q1, while PEG maintained long-term targets including $24B-$28B total capex for 2026-2030 and a 6%-7.5% rate base CAGR. Management reaffirmed its 2026 EPS guidance of $4.28-$4.40, representing ~7% growth at the midpoint. Both residential electric and gas customers increased ~1% on a trailing-12-month basis, which we think reflects continued execution of the regulated investment program. Annualized dividends were increased ~6% to $2.68 for 2026. We view this as a competitive growth rate amongst Multi-Utility peers.

$PEG
Australia

Merck Completes Terns Pharmaceuticals Acquisition

Merck (MRK) said Tuesday it has completed the acquisition of Terns Pharmaceuticals after a cash tender offer at $53 per share.Terns' stock will no longer be listed on Nasdaq, it said.The deal will result in a charge to research and development expense of about $2.35 per share, included in Q2 and full year 2026 GAAP and non-GAAP results, Merck said.GAAP and non-GAAP EPS are also expected to take a hit of about $0.12 a share in 2026 on costs associated with advancing TERN-701 and costs of financing, it added.Price: $113.21, Change: $+0.10, Percent Change: +0.09%

$MRK$TERN